KALV Similar Chart Price Prediction
The price of KALV is predicted to go up 5.95%, based on the high correlation periods with ESTC. The similarity of these two price pattern on the periods is 97.52%.
KALV
ESTC
Up: 5.95%Similarity: 97.52%
KALV Revenue Forecast
KALV EPS Forecast
KALV FAQs
What is KALV eps forecast for next quarter？
KALV Analyst's Forecast
Jonathan Wolleben
JMP Securities
Buy
2025-01-31
Price Target
$19
Upside
+113.24%
JMP Securities initiated coverage of KalVista with an Outperform rating and $19 price target. KalVista is developing sebetralstat, a small-molecule plasma kallikrein inhibitor, which could be the first oral on-demand therapy for hereditary angioedema and take "substantial" market share from currently approved injectables, the analyst tells investors in a research note. The firm sees approval as likely by the June 17 FDA action date.
Stacy Ku
TD Cowen
Strong Buy
2025-01-07
Price Target
$30
Upside
+242.47%
Tazeen Ahmad
B of A Securities
Strong Buy
2024-12-18
Price Target
$22
Upside
+160.05%
